SPRO
Spero Therapeutics, Inc.
1.17
USD
This page is just a preview of the data found in TrendSpider’s full version
Spero Therapeutics, Inc. stock is down -1.68% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 December’s closed higher than November. 100% of analysts rate it a buy.
Spero Therapeutics, Inc. focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults.
